AR086907A1 - Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17 - Google Patents
Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17Info
- Publication number
- AR086907A1 AR086907A1 ARP120102076A ARP120102076A AR086907A1 AR 086907 A1 AR086907 A1 AR 086907A1 AR P120102076 A ARP120102076 A AR P120102076A AR P120102076 A ARP120102076 A AR P120102076A AR 086907 A1 AR086907 A1 AR 086907A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- psa
- patient
- psoriatic arthritis
- antagonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 206010003246 arthritis Diseases 0.000 title 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 14
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 14
- 108700028369 Alleles Proteins 0.000 abstract 2
- 229960004540 secukinumab Drugs 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000011338 personalized therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rehabilitation Therapy (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Métodos predictivos y terapias personalizadas para el tratamiento de artritis psoriásica (PsA). De una manera específica, esta divulgación se refiere a métodos para el tratamiento de un paciente que tenga artritis psoriásica (PsA) mediante la administración, selectivamente, de un antagonista de IL-17, por ejemplo, un anticuerpo de IL-17, tal como secukinumab, al paciente con artritis psoriásica (PsA), con base en que el paciente tenga una predisposición a tener una respuesta favorable al tratamiento con el antagonista de IL-17. También en la presente se dan a conocer métodos de diagnóstico útiles para predecir la probabilidad de que un paciente que tenga artritis psoriásica (PsA) responderá al tratamiento con un antagonista de IL-17, por ejemplo, con un anticuerpo de IL-17, tal como secukinumab.Reivindicación 20: Un antagonista de IL-17 para utilizarse en el tratamiento de artritis psoriásica (PsA), caracterizado porque se administra al paciente una cantidad terapéuticamente efectiva del antagonista de IL-17, con base en que el paciente tenga un alelo de artritis psoriásica (PsA) con respuesta, o con base en que el paciente no tenga un alelo de artritis psoriásica (PsA) sin respuesta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ3702011 | 2011-11-21 | ||
| US201261624564P | 2012-04-16 | 2012-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086907A1 true AR086907A1 (es) | 2014-01-29 |
Family
ID=48470189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102076A AR086907A1 (es) | 2011-11-21 | 2012-06-11 | Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150064193A1 (es) |
| EP (1) | EP2783014A1 (es) |
| JP (1) | JP2015504430A (es) |
| KR (1) | KR20140097178A (es) |
| CN (1) | CN104011223A (es) |
| AR (1) | AR086907A1 (es) |
| AU (1) | AU2012341081B2 (es) |
| BR (1) | BR112014012101A2 (es) |
| CA (1) | CA2856252A1 (es) |
| MX (1) | MX2014006158A (es) |
| RU (1) | RU2014125071A (es) |
| WO (1) | WO2013077907A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
| TWI616204B (zh) | 2010-11-05 | 2018-03-01 | 諾華公司 | Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途 |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
| HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| AU2015258859B2 (en) | 2014-05-15 | 2020-07-23 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| CN115944734A (zh) * | 2014-09-10 | 2023-04-11 | 诺华股份有限公司 | 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展 |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016118921A1 (en) * | 2015-01-24 | 2016-07-28 | Abbvie, Inc. | Compositions and methods for treating psoriatic arthritis |
| MY196489A (en) | 2015-10-27 | 2023-04-17 | UCB Biopharma SRL | Methods of Treatment Using Anti-IL-17A/F Antibodies |
| MA55149A (fr) * | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| KR20220016954A (ko) * | 2019-06-04 | 2022-02-10 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법 |
| CA3155108A1 (en) * | 2019-09-20 | 2021-03-25 | Novartis Ag | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists |
| AU2022232007A1 (en) * | 2021-03-12 | 2023-10-26 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
| MX2023010705A (es) * | 2021-03-12 | 2023-11-22 | Janssen Biotech Inc | Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23. |
| CN114427001A (zh) * | 2022-01-29 | 2022-05-03 | 中日友好医院(中日友好临床医学研究所) | 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| EP3366702B1 (en) | 2005-12-13 | 2023-08-09 | Eli Lilly And Company | Anti-il-17 antibodies |
| KR20080099290A (ko) | 2006-01-31 | 2008-11-12 | 노파르티스 아게 | 암 치료용 ｉｌ-17 길항 항체 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| BRPI0813262A2 (pt) * | 2007-06-20 | 2015-04-14 | Schering Corp | Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a |
| MY153893A (en) | 2008-09-29 | 2015-04-15 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| WO2011014349A1 (en) * | 2009-07-28 | 2011-02-03 | Centocor Ortho Biotech Inc. | Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis |
| EP4137514A1 (en) * | 2010-10-08 | 2023-02-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| AR084234A1 (es) * | 2010-12-13 | 2013-05-02 | Novartis Ag | Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) |
-
2012
- 2012-06-07 BR BR112014012101A patent/BR112014012101A2/pt not_active IP Right Cessation
- 2012-06-07 CA CA2856252A patent/CA2856252A1/en not_active Abandoned
- 2012-06-07 CN CN201280057295.5A patent/CN104011223A/zh active Pending
- 2012-06-07 KR KR1020147013196A patent/KR20140097178A/ko not_active Withdrawn
- 2012-06-07 AU AU2012341081A patent/AU2012341081B2/en not_active Ceased
- 2012-06-07 US US14/358,504 patent/US20150064193A1/en not_active Abandoned
- 2012-06-07 WO PCT/US2012/041310 patent/WO2013077907A1/en not_active Ceased
- 2012-06-07 JP JP2014542299A patent/JP2015504430A/ja active Pending
- 2012-06-07 RU RU2014125071/10A patent/RU2014125071A/ru not_active Application Discontinuation
- 2012-06-07 MX MX2014006158A patent/MX2014006158A/es unknown
- 2012-06-07 EP EP12727081.7A patent/EP2783014A1/en not_active Withdrawn
- 2012-06-11 AR ARP120102076A patent/AR086907A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2783014A1 (en) | 2014-10-01 |
| JP2015504430A (ja) | 2015-02-12 |
| US20150064193A1 (en) | 2015-03-05 |
| MX2014006158A (es) | 2014-06-19 |
| CN104011223A (zh) | 2014-08-27 |
| AU2012341081A1 (en) | 2014-05-29 |
| CA2856252A1 (en) | 2013-05-30 |
| WO2013077907A1 (en) | 2013-05-30 |
| BR112014012101A2 (pt) | 2019-09-24 |
| KR20140097178A (ko) | 2014-08-06 |
| RU2014125071A (ru) | 2015-12-27 |
| AU2012341081B2 (en) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086907A1 (es) | Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17 | |
| CY1123079T1 (el) | Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων | |
| PA8847001A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| GT201200293A (es) | Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) | |
| BR112012022214A2 (pt) | métodos e composições para tratar doença de degos | |
| AR084234A1 (es) | Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| ECSP14004893A (es) | Moléculas de unión para bcma y cd3 | |
| BR112014021251A2 (pt) | anticorpos humanos para toxinas de clostridium difficile | |
| MX357820B (es) | Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva. | |
| PE20081501A1 (es) | Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos | |
| NI201300057A (es) | Mutantes fc de anticuerpos resistentes a proteasas activas | |
| CR20170097A (es) | Compuestos terapéuticamente activos y sus métodos de uso (divisional) | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| PE20130646A1 (es) | Anticuerpos antagonistas anti receptor de il-7 y procedimientos | |
| BR112013026828A2 (pt) | polipeptídeos de anticorpo que antagonizam cd40 | |
| AR090738A1 (es) | Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17 | |
| EA200802247A1 (ru) | Схема дозирования кладрибина для лечения рассеянного склероза | |
| CL2011001760A1 (es) | Combinación que comprende metotrexato y un inhibidor de dhodh no hepatotóxico; y uso en el tratamiento de enfermedades tales como artritis psoriatica, esclerosis multiple, psoriasis, entre otras. | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| BR112015008143A2 (pt) | complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições | |
| UA105405C2 (ru) | Гуманизированное антитело против человеческого il-22ra | |
| AR092981A1 (es) | Biomarcadores predictivos de la respuesta clinica al acetato de glatiramero | |
| BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |